thumbnail
Facilities & CapacityNovo Holdings $16.5bn Catalent buy to boost fill-finish for Novo NordiskNovo Holdings to buy CDMO Catalent for $16.5bn
Investment firm Novo Holdings will take CDMO Catalent private and sell three of its drug product manufacturing facilities to its company Novo Nordisk.